Search Results

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the first quarter of 2024.

Medigene AG announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell therapies.

Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced the submission of three patents to the European Patent Office.

Medigene AG will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024.